Can KCa3.1 channel activators serve as novel inhibitors of platelet aggregation?
- PMID: 36271464
- DOI: 10.1111/jth.15863
Can KCa3.1 channel activators serve as novel inhibitors of platelet aggregation?
Comment on
-
Inhibition of platelet aggregation by activation of platelet intermediate conductance Ca2+ -activated potassium channels.J Thromb Haemost. 2022 Nov;20(11):2587-2600. doi: 10.1111/jth.15827. Epub 2022 Aug 7. J Thromb Haemost. 2022. PMID: 35867883
References
REFERENCES
-
- Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, Maylie J. A human intermediate conductance calcium-activated potassium channel. Proc Natl Acad Sci U S A. 1997;94:11651-11656.
-
- Gardos G. The function of calcium in the potassium permeability of human erythrocytes. Biochem Biophys Acta. 1958;30:653-654.
-
- Vandorpe DH, Shmukler BE, Jiang L, et al. cDNA cloning and functional characterization of the mouse Ca2+-gated K+ channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. J Biol Chem. 1998;273:21542-21553.
-
- Brown BM, Shim H, Christophersen P, Wulff H. Pharmacology of small- and intermediate-conductance calcium-activated potassium channels. Annu Rev Pharmacol Toxicol. 2020;60:219-240.
-
- Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood. 2008;111:3991-3997.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
